Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Ghader Mohammadnezhad, Melika Sattarpour & Najmeh Moradi. (2022) Budget impact analysis of breast cancer medications: a systematic review. Journal of Pharmaceutical Policy and Practice 15:1.
Read now
Read now
Bhavik J. Pandya, Hongbo Yang, Cynthia Schmeichel, Cynthia Z. Qi & Manasee V. Shah. (2021) A budget impact analysis of gilteritinib for the treatment of relapsed or refractory FLT3mut+ acute myeloid leukemia in a US health plan. Journal of Medical Economics 24:1, pages 19-28.
Read now
Read now
Lei Wu & Lixian Zhong. (2019) Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Journal of Medical Economics 22:2, pages 187-195.
Read now
Read now
Rohit Mistry, Gaurav Suri, Kate Young, Robert Hettle, Jessica R. May, Diana Brixner, Gary Oderda, Joseph Biskupiak, Derek Tang, Devarshi Bhattacharyya, Subrata Bhattacharyya, Dinesh Mishra & Anand A. Dalal. (2018) Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2− advanced or metastatic breast cancer. Current Medical Research and Opinion 34:12, pages 2143-2150.
Read now
Read now
Nanxin Li, Yanni Hao, Valerie Koo, Anna Fang, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu & Annie Guérin. (2016) Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2− metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. Journal of Medical Economics 19:4, pages 414-423.
Read now
Read now
Mona Chitre & Kristen M Reimers. (2014) Considerations for payers in managing hormone receptor-positive advanced breast cancer. ClinicoEconomics and Outcomes Research 6, pages 331-339.
Read now
Read now
Jipan Xie. (2014) Author response. Journal of Medical Economics 17:9, pages 617-617.
Read now
Read now
Vakaramoko Diaby, Georges Adunlin & Alberto J. Montero. (2014) Letter to the Editor. Journal of Medical Economics 17:4, pages 248-249.
Read now
Read now
Chan Shen, Chun-Ru Chien, Daniel M Geynisman, Fabrice Smieliauskas & Ya-Chen T Shih. (2014) A review of economic impact of targeted oral anticancer medications. Expert Review of Pharmacoeconomics & Outcomes Research 14:1, pages 45-69.
Read now
Read now
Articles from other publishers (6)
Daniel StellatoMargaret E. GerbasiBriana NdifeSameer R. GhateAaron MoynahanDinesh MishraPraveen GundaRoy KoruthThomas E. Delea. (2019) Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1227-1237.
Crossref
Crossref
Monika Parisi, Corey Pelletier, Dasha Cherepanov & Michael S Broder. (2018)
Outcomes research examining treatments, quality of life and costs in
HER2
-negative and triple-negative metastatic breast cancer: a systematic literature review
. Journal of Comparative Effectiveness Research 7:1, pages 67-83.
Crossref
Crossref
Josephine Mauskopf & Stephanie Earnshaw. (2016) A Methodological Review of US Budget-Impact Models for New Drugs. PharmacoEconomics 34:11, pages 1111-1131.
Crossref
Crossref
Yanni Hao, Nanxin Li, Anna P. Fang, Valerie Koo, Miranda Peeples, Andrew Kageleiry, Eric Q. Wu & Annie Guérin. (2016) Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. Advances in Therapy 33:6, pages 983-997.
Crossref
Crossref
Vin Cci Ng, Jeremy J Johnson & Sandra Cuellar. (2014) Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer. Journal of Oncology Pharmacy Practice 21:6, pages 433-442.
Crossref
Crossref
Vakaramoko Diaby, Georges Adunlin, Simon B. Zeichner, Kiran Avancha, Gilberto Lopes, Stefan Gluck & Alberto J. Montero. (2014) Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast Cancer Research and Treatment 147:2, pages 433-441.
Crossref
Crossref